Shots:
- Jazz Pharmaceuticals to acquire Chimerix for ~$935M at a price of $8.55 per share in cash. Upon completion in Q2’25, Jazz will acquire remaining shares via second-step merger
- Acquisition will strengthen Jazz’s rare oncology presence through development & launch of Chimerix’s lead asset, dordaviprone, while adding durable revenue potential with patent protection through 2037 & possible extension
- Dordaviprone is under the US FDA priority review (PDUFA: Aug 18, 2025) with potential RPD PRV post approval, plus it is being evaluated in an ongoing P-III (ACTION) trial for naïve, non-recurrent H3 K27M-mutant glioma post-radiation, potentially expanding its use to 1L pts
Ref: Prnewswire | Image: Chimerix
Related News:- Jazz Pharmaceuticals’ Ziihera (Zanidatamab-hrii) Secures the US FDA’s Accelerated Approval to Treat HER2-Positive (IHC 3+) Biliary Tract Cancer (BTC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
